Moxifloxacin Fresenius Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacin Fresenius Kabi, is a fluoroquinolone antibiotic presented as an intravenous solution for intravenous use. It treats a range of serious bacterial infections in adult patients, including community‑acquired pneumonia, acute bacterial sinusitis, skin and soft‑tissue infections, complicated intra‑abdominal infections, and complicated urinary tract infections.

GNH USA supplies Moxifloxacin Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Moxifloxacin is a fluoroquinolone antibiotic used to treat bacterial infections affecting various organ systems.

- Community‑acquired bacterial pneumonia: rapid bacterial eradication and clinical improvement. - Acute bacterial sinusitis: reduction of sinus pathogen load and symptom relief. - Skin and soft‑tissue infections: effective against Gram‑positive and Gram‑negative organisms causing cellulitis and wound infections. - Complicated intra‑abdominal infections: broad‑spectrum coverage for mixed aerobic and anaerobic flora. - Complicated urinary tract infections: eradication of resistant uropathogens in complicated cases.

Moxifloxacin may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhea: loose stools, occasionally watery. - Headache: transient cranial pain. - Elevated liver enzymes: mild, reversible changes in hepatic function tests.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or rupture, especially in the Achilles tendon. - QT interval prolongation: risk of cardiac arrhythmias, particularly in patients with pre‑existing heart disease. - Severe hypersensitivity reactions: anaphylaxis, Stevens‑Johnson syndrome, or toxic epidermal necrolysis.

Moxifloxacin should be used with caution in specific clinical situations.

- Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic dysfunction: assess liver enzymes before and during treatment. - History of tendon disorders: avoid use in patients with prior tendon injury or those on corticosteroids. - Cardiac risk factors: evaluate QT interval and electrolyte status prior to initiation. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at ambient temperature: keep in original container, protect from light and moisture.

Moxifloxacin can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of moxifloxacin. - Warfarin: may increase anticoagulant effect and bleeding risk. - Theophylline: increased plasma levels leading to toxicity. - Cyclosporine: elevated cyclosporine concentrations.

Moderate Interactions (Monitor Closely): - NSAIDs: heightened risk of central nervous system stimulation. - Corticosteroids: additive risk of tendon rupture. - Diabetic agents: potential for altered glucose control.